CSIMarket
 


Syros Pharmaceuticals Inc   (SYRS)
Other Ticker:  
 
 

SYRS's Revenue Growth by Quarter and Year

Syros Pharmaceuticals Inc 's Revenue results by quarter and year




SYRS Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 7.80 5.70 0.51
III Quarter September 3.89 5.70 3.83 0.56
II Quarter June 6.28 5.16 3.19 0.46
I Quarter March 5.47 4.83 2.38 0.45
FY   15.64 23.49 15.10 1.98



SYRS Revenue third quarter 2022 Y/Y Growth Comment
Syros Pharmaceuticals Inc reported fall in Revenue in the third quarter 2022 by -31.74% to $ 3.89 millions, from the same quarter in 2021.
The drop in the third quarter 2022 Syros Pharmaceuticals Inc 's Revenue compares unfavorably to the Company's average Revenue rise of 30%.

Looking into third quarter 2022 results within Major Pharmaceutical Preparations industry 20 other companies have achieved higher Revenue growth. While Syros Pharmaceuticals Inc ' s Revenue drop of -31.74% ranks overall at the positon no. 400 in the third quarter 2022.




SYRS Revenue ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - 36.84 % 1017.65 % -42.7 %
III Quarter September -31.74 % 48.83 % 583.93 % 36.59 %
II Quarter June 21.71 % 61.76 % 593.48 % 21.05 %
I Quarter March 13.25 % 102.94 % 428.89 % 21.62 %
FY   - 55.56 % 662.63 % -3.41 %

Financial Statements
Syros Pharmaceuticals Inc 's third quarter 2022 Revenue $ 3.89 millions SYRS's Income Statement
Syros Pharmaceuticals Inc 's third quarter 2021 Revenue $ 5.70 millions Quarterly SYRS's Income Statement
New: More SYRS's historic Revenue Growth >>


SYRS Revenue (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - 36.84 % 48.83 % -8.93 %
III Quarter September -38.04 % 10.47 % 20.06 % 21.74 %
II Quarter June 14.81 % 6.83 % 34.03 % 2.22 %
I Quarter March -29.87 % -15.26 % 366.67 % -49.44 %
FY (Year on Year)   - 55.56 % 662.63 % -3.41 %




Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #21
Healthcare Sector #51
Overall #400

Revenue Y/Y Growth Statistics
High Average Low
97.12 % 30 % -16.27 %
(Mar 31 2020)   (Dec 31 2019)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #21
Healthcare Sector #51
Overall #400
Revenue Y/Y Growth Statistics
High Average Low
97.12 % 30 % -16.27 %
(Mar 31 2020)   (Dec 31 2019)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Syros Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
368.31 % 31.04 % -100 %
(Mar 31 2020)  


SYRS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Syros Pharmaceuticals Inc realized fall in Revenue from the previous quarter by -38.04% to $ 3.89 millions, from $ 6.28 millions declared a quarter before.

Although seasonal influence commonly elevate III. Quarter 2022 results, this clearly could not be substantial to salvage Major Pharmaceutical Preparations's company performance, Sai Subramanium , market insider pointed out and mentioned that average quarter on quarter Revenue growth is at 31.04% for Syros Pharmaceuticals Inc .

Within Major Pharmaceutical Preparations industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Syros Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 465.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #31
Healthcare Sector #62
Overall #465
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #31
Healthcare Sector #62
Overall #465
Revenue Q/Q Growth Statistics
High Average Low
368.31 % 31.04 % -100 %
(Mar 31 2020)  


SYRS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2022 Syros Pharmaceuticals Inc reported fall in Revenue from the previous quarter by -38.04% to $ 3.89 millions, from $ 6.28 millions declared in the previous reporting period.

Although cyclical circumstance commonly fuel III. Quarter 2022 performance, that simply has not been sufficient to recover Syros Pharmaceuticals Inc 's III. Quarter outcome, Sai Subramanium , market insider wrote and mentioned that average quarter on quarter Revenue growth is at 31.04% for SYRS.

Within Major Pharmaceutical Preparations industry 30 other companies have achieved higher Revenue quarter on quarter growth. While Syros Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 465.


Syros Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Revenue 12 Months Ending $ 23.44 $ 25.24 $ 24.13 $ 23.49 $ 21.38
Y / Y Revenue Growth (TTM) 9.6 % 29.35 % 37.55 % 55.62 % 115.93 %
Year on Year Revenue Growth Overall Ranking # 272 # 66 # 80 # 11 # 1738
Seqeuential Revenue Change (TTM) -7.15 % 4.62 % 2.72 % 9.84 % 9.58 %
Seq. Revenue Growth (TTM) Overall Ranking # 918 # 985 # 379 # 72 # 3145




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2022 period, Syros Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 23 millions, company would post below average annual Revenue growth of 9.58% year on year, if the fiscal year would end at Sep 30 2022.
A slow-down in the Syros Pharmaceuticals Inc 's Revenue growth from the 6.28% growth in Jun 30 2022.

In the Healthcare sector 82 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 66 to 272.

Revenue TTM Q/Q Growth Statistics
High Average Low
97.12 %
30 %
-16.27 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 51
Healthcare Sector # 83
Overall # 272

Revenue TTM Y/Y Growth Statistics
High Average Low
661.5 %
239.68 %
-3.32 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 51
Sector # 155
S&P 500 # 918
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2022 period, Syros Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 23 millions, company would post below average annual Revenue growth of -3.32% year on year, if the fiscal year would end at Sep 30 2022.
A slow-down in the Syros Pharmaceuticals Inc 's Revenue growth from the 6.28% growth in Jun 30 2022.

In the Healthcare sector 82 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 66 to 272.

Revenue TTM Q/Q Growth Statistics
High Average Low
97.12 %
30 %
-16.27 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 51
Healthcare Sector # 83
Overall # 272

Revenue TTM Y/Y Growth Statistics
High Average Low
661.5 %
239.68 %
-3.32 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 51
Sector # 155
S&P 500 # 918




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SYRS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for SYRS's Competitors
Revenue Growth for Syros Pharmaceuticals Inc 's Suppliers
Revenue Growth for SYRS's Customers

You may also want to know
SYRS's Annual Growth Rates SYRS's Profitability Ratios SYRS's Asset Turnover Ratio SYRS's Dividend Growth
SYRS's Roe SYRS's Valuation Ratios SYRS's Financial Strength Ratios SYRS's Dividend Payout Ratio
SYRS's Roa SYRS's Inventory Turnover Ratio SYRS's Growth Rates SYRS's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2022
Owens and Minor inc-0.19%$ -0.191 millions
National Research Corporation-0.20%$ -0.201 millions
Livanova Plc-0.24%$ -0.241 millions
Healthcare Services Group Inc -0.27%$ -0.265 millions
Catalent Inc -0.29%$ -0.293 millions
Asensus Surgical Inc -0.31%$ -0.311 millions
Liquidia Corporation-0.43%$ -0.429 millions
Integra Lifesciences Holdings Corp-0.43%$ -0.432 millions
Pediatrix Medical Group Inc -0.62%$ -0.615 millions
China Pharma Holdings Inc -0.64%$ -0.642 millions
Acadia Pharmaceuticals Inc -0.68%$ -0.682 millions
Amgen Inc -0.81%$ -0.805 millions
Syneos Health Inc -0.89%$ -0.891 millions
Hologic Inc-0.93%$ -0.925 millions
Innovage Holding Corp -1.07%$ -1.070 millions
Procyon Corporation-1.20%$ -1.200 millions
Precipio inc -1.38%$ -1.380 millions
Ati Physical Therapy Inc -1.40%$ -1.397 millions
Ocular Therapeutix Inc -1.55%$ -1.547 millions
Alpine Immune Sciences Inc -1.75%$ -1.750 millions
Surgalign Holdings Inc -1.79%$ -1.786 millions
Tenet Healthcare Corp-1.90%$ -1.900 millions
Teleflex Incorporated-1.92%$ -1.923 millions
Novocure Limited-1.95%$ -1.952 millions
Dynatronics Corporation-2.01%$ -2.014 millions
Royalty Pharma Plc-2.10%$ -2.101 millions
National Healthcare Corp-2.13%$ -2.130 millions
Fonar Corporation-2.27%$ -2.271 millions
Psychemedics Corp-2.35%$ -2.353 millions
Escalon Medical Corp -2.63%$ -2.626 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com